Generation and characterization of a mitotane-resistant adrenocortical cell line [PDF]
Endocrine Connections, 2020 Mitotane is the only drug approved for the therapy of adrenocortical carcinoma (ACC). Its clinical use is limited by the occurrence of relapse during therapy.
Eric Seidel +14 more
doaj +4 more sources
Mitotane-Induced Hypothyroidism and Dyslipidemia in Adrenocortical Carcinoma: Sex Differences and Novel Evidence from a Thyroid Cell Model [PDF]
Current OncologyAdrenocortical carcinoma (ACC) is a rare and aggressive cancer with limited treatment options, commonly managed with mitotane, which can cause serious side effects, including central hypothyroidism and dyslipidemia.
Irene Tizianel +9 more
doaj +2 more sources
Mitotane-Induced Endocrine Alterations in Children with Adrenocortical Carcinoma: Clinical Implications from a 20-Year Retrospective Study [PDF]
ChildrenBackground/Objectives: Mitotane is a key component in the treatment of adrenocortical carcinoma (ACC), but its endocrine side effects in children remain under-characterized. Methods: We conducted a retrospective analysis of 11 pediatric patients (6 males,
Gerdi Tuli +6 more
doaj +2 more sources
Mitotane dosage, plasma levels, and anthropometric measurements in pediatric adrenocortical carcinoma [PDF]
Endocrine OncologyObjective: Mitotane is an effective treatment for advanced adrenocortical carcinoma (ACC). Given the limited pediatric data available, this study aims to evaluate the associations between mitotane dosage, plasma drug levels, and anthropometric ...
Maria Riedmeier +28 more
doaj +2 more sources
Mitotane Treatment for Malignant Leydig Cell Tumor: A Case Report [PDF]
IJU Case ReportsIntroduction Leydig cell tumors (LCTs), constituting 1%–3% of testicular tumors, are mostly benign, but malignant cases present treatment challenges. We report a malignant LCT case with a notable response to mitotane. Case Presentation A 43‐year‐old male
Daiki Katsura +7 more
doaj +2 more sources
Frontiers in Microbiology, 2018 Due to limited new antibiotics, polymyxins are increasingly used to treat multidrug-resistant (MDR) Gram-negative bacteria, in particular carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae.
Yohei Doi, Tony Velkov, Jian Li
exaly +3 more sources
Low-dose mitotane-induced neurological and endocrinological complication in a 5-year-old girl with adrenocortical carcinoma [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2022 Mitotane is an adrenolytic drug that exhibits therapeutic effects within a narrow target range (14–20 μg/dL). Various complications develop if the upper limit is exceeded.
You Joung Heo +9 more
doaj +1 more source
Frontiers in Oncology, 2022 Mitotane is the only drug approved to treat adrenocortical carcinoma (ACC), and a relationship of pharmacokinetic/pharmacodynamic has been characterized.
Xin Liu +20 more
doaj +1 more source
IJU Case Reports, 2022 Introduction The prognosis of patients with unresectable adrenocortical carcinoma is poor. Mitotane is the first‐line treatment for this disease, and etoposide/doxorubicin/cisplatin/mitotane therapy is recommended as first‐line chemotherapy in ...
Yuki Kobayakawa +8 more
doaj +1 more source
CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells. [PDF]
PLoS ONE, 2018 Mitotane is the reference drug for adrenocortical carcinoma (ACC) and the metabolic activation of the drug is considered as essential for its activity. The aim of this study was to assess the role of CYP11B1 on mitotane action and metabolism in H295R ACC
Antonina Germano +7 more
doaj +1 more source